1. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzosin for the treatment of benign prostatic hypertrophy. Lancet 1991;337:1457.
2. Peters CA, Walsh PC. The effect of nafarelin acetate a luteinizing-hormone-releasinghormone agonist on benign prostatic hyperplasia. N Engl J Med 1987;317:599.
3. Bosch RJ, Griffiths DJ, Blom J, Schroeder FH. Treatment of benign prostatic hyperplasia by androgen deprivation: Effects on prostate size and urodynamic parameters. J Urol 1989;141:68.
4. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patient with benign prostatic hyperplasia. J Urol 1993;150:359.
5. Kumar VL, Dewan S. Alpha adrenergic blockers in the treatment of benign hyperplasia of the prostate. Int Urol Nephrol 2000;32:67.
6. Cuellar DC, Kyprianou N. Future concepts in the medical therapy of benign prostatic hyperplasia. Curr Opin Urol 2001;11:27.
7. Stuart JD, Lee FW, Simpson Noel D, Kadwell SH, Overton LK, Hoffman CR. Pharmacokinetic parameters and mechanism of inhibitor of rat type-1 and 2 steroid 5-alpha-reductase:determinants for different in vivo activities of G1198745 and finasteride in the rat. Bioch Pharmacol 2001;62:933.